Additional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed median progression-free survival (“PFS”) ...
Hosted on MSN
Lytix Biopharma’s promising update: Phase 2 study on advanced melanoma treatment completed
Lytix Biopharma AS (DE:6BG) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination With ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback